Circular RNAs (circRNAs) have emerged as important regulators in cancer biology. They are characterized by increased stability compared with linear RNAs, are often present at high abundance, and can exhibit tissue-specific expression patterns. These properties underpin growing interest in circRNAs as functional molecules that influence tumor cell biology and as candidates for clinical biomarker development.
The reviewed article frames circRNAs as modulators of key signaling pathways implicated in cancer and highlights their particular interactions with the Hippo pathway, a conserved regulator of cell proliferation, apoptosis, and organ size. Dysregulation of Hippo signaling has been associated with multiple malignancies, and circRNA-mediated effects on this pathway appear to contribute to tumorigenesis and disease progression.
The Hippo pathway is a central signal transduction cascade that governs cell growth and tissue homeostasis. In cancer, dysregulated Hippo signaling is linked to enhanced proliferative capacity, survival, and other malignant phenotypes. The review underscores that alterations in Hippo pathway components or activity are observed across various tumor types and that restoring appropriate Hippo signaling can alter tumor behavior.
Although the source review does not enumerate individual Hippo components or specific molecular interactions in detail, it emphasizes the pathway’s broad relevance to cancer pathogenesis and its susceptibility to regulation by noncoding RNAs, including circRNAs.
The review synthesizes available evidence that circRNAs can influence Hippo pathway activity. Across cancer types, circRNAs display aberrant expression profiles, and some of these circRNAs interact—directly or indirectly—with Hippo signaling to modify downstream outputs relevant to tumor growth and metastasis.
Specific mechanistic descriptions, case examples, and quantitative results are not reported in the abstract. However, the authors state that circRNA–Hippo interactions represent a recurring theme in recent cancer research and that modulation of the Hippo cascade by circRNAs materially affects tumorigenesis in experimental systems.
Aberrant expression of circRNAs that affect the Hippo pathway has been correlated with clinical features and patient prognosis in multiple cancers. The review highlights circRNAs’ potential as diagnostic and prognostic biomarkers because their stability and tissue specificity facilitate detection and may reflect tumor biology tied to Hippo pathway status.
The authors argue that profiling circRNA expression and understanding circRNA-driven modulation of Hippo signaling could improve risk stratification and inform prognostic assessment. The abstract does not provide detailed lists of candidate circRNAs or diagnostic performance metrics; those specifics were not reported in the source summary.
The review reports that therapeutic approaches aimed at disrupting or harnessing circRNA–Hippo interactions have shown promise in preclinical studies. These strategies, as summarized in the abstract, can modify Hippo pathway activity and thereby influence tumor growth or progression in experimental settings.
Details about the specific therapeutic modalities, delivery systems, model systems, or efficacy measures are not included in the abstract. The authors indicate, however, that such preclinical work supports the feasibility of targeting circRNA–Hippo interactions as a novel anticancer strategy.
The authors identify the need for comprehensive mechanistic studies to elucidate how circRNAs regulate the Hippo pathway across cancer types. Key priorities include clarifying direct molecular interactions, establishing causality between specific circRNAs and Hippo-driven phenotypes, and validating candidate biomarkers and therapeutic targets in clinical cohorts.
Translational challenges emphasized in the review include the gap between preclinical promise and clinical implementation. The abstract calls for efforts to translate mechanistic insights into validated diagnostic assays, prognostic tools, and safe, effective therapeutics that modulate circRNA–Hippo interactions.
In summary, the review presents the interaction between circRNAs and the Hippo pathway as a significant axis in cancer biology with diagnostic, prognostic, and therapeutic relevance. While preclinical models demonstrate the potential to manipulate this axis for antitumor effects, the article stresses that additional mechanistic research and clinical validation are required before circRNA profiling or targeted therapies can be widely integrated into patient care. Integrating circRNA analysis into clinical workflows may ultimately advance cancer diagnosis, prognosis, and personalized treatment, but further work is needed to realize these goals.
(Notes: specific experimental data, lists of individual circRNAs, and quantitative results were not reported in the abstract and therefore are not included here.)